US Stock Market Movement: BioNTech plunges on October 13 as BNT113 fails to meet PFS endpoint
Bitget异动解读2026/10/13 11:51BioNTech October 13 Major Drop Analysis
Keywords: BNT113 did not meet PFS endpoint
On October 13, 2026, BioNTech announced the results of the AHEAD-MERIT phase 2/3 trial. BNT113 combined with pembrolizumab did not show a significant improvement in progression-free survival compared to pembrolizumab monotherapy, and did not achieve the first dual primary endpoint; overall survival is still under evaluation. These results indicate that the candidate therapy has not yet shown a statistically significant advantage in the primary efficacy endpoint.
(Disclaimer: This content is summarized from publicly available information collected by AI technology, for reference only and does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Renowned analyst revises outlook: Tech giants' capital expenditures to peak in 2027, cash shortages may be exposed earlier
Ives predicts that tech giants' capital expenditures will peak in 2027, free cash flow will bottom out in the first half of next year, and a cash flow inflection point will be reached in 2029.
Euro advances on ECB rate hike expectations, weaker US Dollar
Crypto prices
More
